Top Markets
Coin of the day
Odyssey Therapeutics, Inc. Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc.

ODTX
Pozycja w akcjach #8753
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused... Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Cena akcji
$24.55
Ostatnia synchronizacja: 2026-08-28
Kapitalizacja rynkowa
$1.18B
Zmiana (1 dzień)
-5.50%
Zmiana (1 rok)
-
Kraj
US
Handel Odyssey Therapeutics, Inc. (ODTX)

Kategoria

EPS dla Odyssey Therapeutics, Inc. (ODTX)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy Odyssey Therapeutics, Inc., obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla Odyssey Therapeutics, Inc. od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów
Firma EPS Różnica w EPS Kraj
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH